Additionally, research on PDS in other cancer types, such as breast and colorectal cancers, indicates that functional p53 deficiency plays a critical role in the development of treatment resistance, including resistance to cisplatin-based chemotherapy. This evidence concerns the gene TP53 and colorectal cancer.